Aniara | Shaping the Future with Innovative Solutions


Aniara News

Wednesday, November 4, 2009

Measuring the APC Resistance V Associated with Factor V-L, Quantitatively with the Hyphen Biomed kit

Measuring the APC Resistance V associated with Factor V-L, quantitatively
With The Hyphen Biomed Kit
FDA Approved (510K)

Click here for product page

Clinical background

The Factor V-L is insensitive to the action of Activated Protein C. Its presence induces a prolonged coagulant activity in blood (due to a prolonged survival of Factor Va activity), following activation of coagulation. Patients with Factor V-L (mutation R506Q), are exposed to an increased thrombotic risk. This risk, already present in heterozygous patients, where the Normal Factor V and Factor V-L are both present, is strongly enhanced in homozygous patients, who only have Factor V-L.
HEMOCLOT Quanti. V-L (ACK065L) kit is a clotting method proposed for measuring Factor V-L (Factor V Leiden) concentration in citrated plasma, by its resistance to the action of Activated Protein C (APC). The assay is performed in the presence of Activated Protein C. In presence of APC and Protein S (in excess), the prolongation of clotting time is directly related to the concentration of Normal Factor V, and inversely related to the amount of Factor V-Leiden (mutation R506Q).inhibition IIa Fibrinogen (in excess) Fibrin (Coagulation) II (in excess) PLPCa2+Or No inhibition PLPCa2+APC / PSXaVV-L

Assay characteristics

.Quantitative reagent for measuring Factor V-L.
.No interference of plasma factor deficiencies (Other than that of Factor V).
.Excellent discrimination between Heterozygous, Homozygous and Normals.
.Single test method performed with only a Clotting Time (CT).

Assay principle

The HEMOCLOT QuantiV-L Kit is a clotting method, triggered by purified Factor Xa, containing Phospholipids and Calcium, and is performed on the diluted tested plasma, in presence of Activated Protein C and Protein S. In the first step, the diluted plasma is mixed with purified clotting Factors (clotting mixture containing Prothrombin, Fibrinogen, Protein S and Activated Protein C (APC)), in a constant and optimized concentration. Then, the purified Factor Xa in presence of Phospholipids (PLP) is added. Clotting is initiated by the addition of Calcium (Ca2+). The clotting time is then recorded. Clotting time measured is inversely proportional to the concentration of factor V-L. There is an inverse linear relationship, on a bi logarithmicgraph paper, between the factor V-L concentration and the corresponding clotting time.

HEMOCLOT Quanti. V-L is now CE Marked and 510(k) approved

For more product information please follow this link.

Jonas Kingo
Executive Vice President of Global Marketing and Sales
A true partnership is a win win for everybody

Bookmark and Share



RSS Feed

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.